VALIDATION: Advances in the Validation of Chromatographic Processes - Improvements in process validation approaches have resulted in better process understanding. - BioPharm International


VALIDATION: Advances in the Validation of Chromatographic Processes
Improvements in process validation approaches have resulted in better process understanding.

BioPharm International

Before performing validation studies and conformance runs, column packing is validated. Ranges for process control parameters (e.g., flow rate, load, pH, conductivity) will be established in characterization studies. Engineering runs will be performed at production scale. Before confirming scale up, it will be necessary to determine if any modifications resulting from scale changes might alter the process control parameters or product critical quality attributes.

Column storage will be validated by evaluating packing integrity (e.g., frontal analysis, removal of storage agents, any residues removed by the cleaning effect of storage, and control over bioburden.

Column cleaning will be validated by a combination of small-scale prospective studies and concurrent in-process analysis at manufacturing scale.


Experience over the last decade in developing and producing biotherapeutics has enabled the development of a structured approach to process validation that begins in development and continues throughout the lifetime of the product. Although process analytical technologies continue to be discussed as a means for achieving better quality and process control, the need for process validation does not appear to be going away. Improvements in analytical methods have improved our understanding of downstream intermediates and final purified products. These analytical tools enhance the value of process validation. Improvements in process validation approaches have resulted in better process understanding that enables better control over variability—the intent of process validation. The use of enhanced analysis and feedback control, process development, statistical analysis, and characterization studies to establish robust processes have led to the ability to define a space in which the process delivers the critical quality attributes.


The Polymerase Chain Reaction (PCR) is covered by patents owned by Roche Molecular Systems and F. Hoffman-LaRoche. A license to use the PCR process for certain research and development activities accompanies the purchase of certain reagents from licensed suppliers.

Gustav Rodrigo and Maria Murby, GE Healthcare Life Sciences R&D, Uppsala, Sweden, are gratefully acknowledged for providing the data from the DoE study on Capto S.

All illustrations are reproduced with the permission of GE Healthcare Bio-Sciences AB, a General Electric Company, Bjorkgatan, Uppsala, Sweden.

Gail Sofer is director of regulatory compliance at the life sciences business unit of GE Healthcare, and a member of BioPharm International’s Editorial Advisory Board, 732.457.8000,
Mattias Ahnfelt is senior research engineer and black belt in Six Sigma at the life sciences business unit of GE Healthcare, +46 18 612 1990,


1. International Conference on Harmonization. Q8, pharmaceutical development. Geneva, Switzerland; 2005.

2. International Conference on Harmonization. Q9, quality risk management. Geneva, Switzerland; 2005.

3. Seely JE, Seely RJ. A rational, step wise approach to process characterization. BioPharm Int. 2003;16(8): 24–34.

4. Murtagh J. Development of a bio-derived drug. Contract pharma. 2006;8(3):70–75.

5. Mollah AH. Application of FMEA for process risk assessment. 2005;3(10):12–22.

6. Brorson K, et al. Impact of cell culture process changes on endogenous retroviral expression. Biotechnol. bioeng. 2002;80(3):257–67.

7. Application Note 28-4078-17 AA, Capto S cation exchanger for post-protein A purification of monoclonal antibodies. Chalfont St. Giles, UK; 2006.

8. US Food and Drug Administration. Guidance for industry. General principles of process validation. Rockville, MD; May 2006.

9. Rathore A. Efficiency measurements for chromatography columns. BioPharm Int. 2005;18(8):58–64.

10. US Food and Drug Administration. Therapeutic compliance guide. 7341.001.

11. Norling L, et al. Impact of multiple re-use of anion-exchange chromatography media on virus removal. J Chrom A. 2005;1069(1):79–89.

12. Brorson K, et al. Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J Chrom A. 2003;989(1):153–163.

13. International Conference on Harmonization. Q 5A, viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Geneva, Switzerland; 1997.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here